BRCA2 and ovarian cancer: The breast and ovarian cancer incidences in BRCA1 and BRCA2 mutation carriers are now based on a much larger number of mutation-carrying families and are, therefore, more reliable; the variance of the polygenic component is now age dependent as opposed to constant; and the incidences vary gradually with age and are cohort and calendar period specific.